In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price ...

BioNTech SE (NASDAQ:BNTX), a biotechnology company renowned for its mRNA technology platform and COVID-19 vaccine success, is navigating a crucial phase in its evolution. With a market capitalization ...

In a report released today, Jessica Fye from J.P. Morgan maintained a Hold rating on BioNTech SE (BNTX – Research Report), with a price target ...

Atomi Financial Group Inc. raised its stake in BioNTech SE (NASDAQ:BNTX – Free Report) by 6.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional ...

PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Healthcare and vaccine stocks are likely to be in the spotlight on Wednesday as Robert F. Kennedy Jr., U.S. President Donald Trump's pick to run the Department of Health and Human Services, is due to ...

European equities traded in the US as American depositary receipts were trending lower late Tuesday morning, declining 0.73% to 1,352.77 on the S&P Europe Select ADR Index. From continental Europe, ...

How expensive is the stock market right now? BioNTech (NASDAQ: BNTX) vaulted into the spotlight in 2020 when Pfizer teamed up with the then-small German company to develop a COVID-19 vaccine.

You can find more details about BNTX stock by going to one of our multiple sections under this page such as historical data, price charts, technical analysis and others.